Hyatt Regency, Boston, United States, Boston
17/04/2012
At the meeting you will learn innovative and fresh content including:
• How the increased requirements by the FDA and the new EU regulations and will affect you • How to effectively meet the challenges associated with the changing global regulatory environment • How can transparency difficulties in pharmacovigilance be overcome? • Is it possible to achieve global harmonization of safety regulations and practices? • How to improve and strengthen risk management strategies throughout the lifecycle of a drug • How to capture and categorise the benefit risk profile of a drug • The role of DSURs and PSURs in drug safety • How to employ a successful signal detection strategy • What impacts are advancing technologies such as predictive science and personalised medicine having on drug safety? • How to overcome infrastructure challenges in drug safety departments • What are the drug safety challenges of the future?
Organized by:
Health Network Communications
Invited Speakers:
Cheryl Watton Vice President Global Safety and Epidemiolology Allergan
George McCormick Vice President Drug Safety and Disposition Cephalon, Inc.
Dr Diego Wyszynski Global Safety Medical Director and Head Maternal and Paediatric Safety (MAPS) Amgen
Dr Mariette Boerstoel- Streefland Chief Safety Officer, Vice president Global Drug Safety, Forest Research Institute Forest Laboratories